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Abstract
Background: There is substantial burden of seasonal influenza in Kenya, which led the government to consider
introducing a national influenza vaccination programme. Given the cost implications of a nationwide programme,
local economic evaluation data are needed to inform policy on the design and benefits of influenza vaccination.
We set out to estimate the cost-effectiveness of seasonal influenza vaccination in Kenya.
Methods: We fitted an age-stratified dynamic transmission model to active surveillance data from patients with
influenza from 2010 to 2018. Using a societal perspective, we developed a decision tree cost-effectiveness model
and estimated the incremental cost-effectiveness ratio (ICER) per disability-adjusted life year (DALY) averted for
three vaccine target groups: children 6–23 months (strategy I), 2–5 years (strategy II) and 6–14 years (strategy III)
with either the Southern Hemisphere influenza vaccine (Strategy A) or Northern Hemisphere vaccine (Strategy B) or
both (Strategy C: twice yearly vaccination campaigns, or Strategy D: year-round vaccination campaigns). We
assessed cost-effectiveness by calculating incremental net monetary benefits (INMB) using a willingness-to-pay
(WTP) threshold of 1–51% of the annual gross domestic product per capita ($17–$872).
Results: The mean number of infections across all ages was 2–15 million per year. When vaccination was well
timed to influenza activity, the annual mean ICER per DALY averted for vaccinating children 6–23 months ranged
between $749 and $1385 for strategy IA, $442 and $1877 for strategy IB, $678 and $4106 for strategy IC and $1147
and $7933 for strategy ID. For children 2–5 years, it ranged between $945 and $1573 for strategy IIA, $563 and
$1869 for strategy IIB, $662 and $4085 for strategy IIC, and $1169 and $7897 for strategy IID. For children 6–14 years,
it ranged between $923 and $3116 for strategy IIIA, $1005 and $2223 for strategy IIIB, $883 and $4727 for strategy
IIIC and $1467 and $6813 for strategy IIID. Overall, no vaccination strategy was cost-effective at the minimum ($17)
and median ($445) WTP thresholds. Vaccinating children 6–23 months once a year had the highest mean INMB
value at $872 (WTP threshold upper limit); however, this strategy had very low probability of the highest net
benefit.
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Conclusion: Vaccinating children 6–23 months once a year was the most favourable vaccination option; however,
the strategy is unlikely to be cost-effective given the current WTP thresholds.
Keywords: Dynamic transmission model, Economic evaluation, Cost-effectiveness, Influenza vaccine, Low- and
middle-income countries, Vaccine timing, Vaccine target group
Background
Influenza is an important cause of respiratory illness in
Kenya, especially in children under 5 and, in particular,
young children under 2 [1, 2]. In 2016, the Kenya Na-
tional Immunisation Technical Advisory Group (KENI
TAG) recommended annual seasonal influenza vaccin-
ation for children 6–23months of age [3]. KENITAG
further recommended pilot projects to generate add-
itional local data to inform implementation of a nation-
wide influenza vaccination policy. In particular, KENI
TAG requested that local evidence be generated on in-
fluenza vaccine cost-effectiveness, because their recom-
mendation largely relied on studies in non-African
countries [4–6]. Given the cost implications of a nation-
wide programme, local economic evaluation data are
needed to inform policy on the design and benefits of in-
fluenza vaccination in Kenya.
In countries with year-round influenza activity, the
World Health Organization (WHO) recommends vac-
cination with the most recent influenza vaccine formula-
tion before the primary peak in influenza activity [7, 8].
In Kenya, cases are observed year round [9], with an
equal number of cases occurring during the Northern
Hemisphere (NH) and Southern Hemisphere (SH) sea-
sons [10]. There are no published influenza vaccine
cost-effectiveness studies in Kenya. In other tropical set-
tings with year-round influenza transmission, there is
some quantification of the effect of elderly vaccination
[11], but no evidence of the impact of vaccinating
children.
Although evidence from intervention and observa-
tional studies on the indirect effects of influenza vaccin-
ation is limited [12], dynamic transmission models have
proven useful to evaluate the effect of public health in-
terventions targeted at infectious diseases, because they
incorporate direct and indirect effects of vaccination [13,
14]. By doing so, it is possible to identify the optimal tar-
get group and coverage level for vaccination pro-
grammes, especially where the impact of herd immunity
significantly alters disease incidence and outcomes [15].
Using a dynamic transmission model, researchers in
the United Kingdom (UK) showed that expanding the
influenza vaccination programme to include children 5–
16 years of age would be the most efficient strategy in
further reducing morbidity and mortality associated with
influenza in their country [16]. We adapted this age-
stratified transmission model to estimate the burden of
disease associated with seasonal influenza from 2010 to
2018 in Kenya. Our objectives were to identify the most
cost-effective target group and to estimate the ideal
timing and vaccine formulation by comparing the
incremental cost-effectiveness ratios (ICER) per
disability-adjusted life year (DALY) averted for different
vaccination scenarios. This information may assist policy
makers in determining optimal seasonal influenza vac-
cination strategies.
Methods
We obtained influenza surveillance data among patients
hospitalised with severe acute respiratory illness (SARI)
in Kenya from 2010 to 2018 and defined peaks in influ-
enza activity. We fitted a transmission dynamic model to
these epidemics by fitting the number of SARI cases, the
number of tested samples and the number of influenza
virus-positive samples, by week and age group (< 1, 1–5,
6–14, 15–19, 20–49 and ≥ 50 years of age). The virus-
positive samples were categorised by influenza type and
subtype: influenza B, influenza A H1N1pdm09
(A(H1N1)pdm09) and influenza A H3N2 (A(H3N2)).
We set each influenza year from September to August
the following year, except at the start of the study period
because data were available from January 2010. Using
epidemiological information, we then estimated the
number of asymptomatic cases, symptomatic cases,
deaths and DALYS due to influenza each year. Using
health care utilisation data and costs of illness, we deter-
mined the number of health care utilisation events and
costs of influenza each year. Thereafter, we modelled dif-
ferent influenza vaccination strategies and determined
the ICER per DALY averted and incremental net monet-
ary benefit (INMB) of each vaccination strategy.
Influenza surveillance data
We used weekly numbers of patients hospitalised with
SARI identified through the Kenyan national SARI sur-
veillance system from 1 January 2010 to 31 December
2018 (Additional file 1). This system is run by the Minis-
try of Health in a few health facilities and supported by
the Centers for Disease Control and Prevention (CDC),
Kenya [9]. There are approximately 759 hospitals with
inpatient capacity in the country, of which 50 have a bed
capacity of ≥200 [17]. We used data from 5 of these
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larger health facilities: Siaya, Nyeri, Mombasa, Nakuru
and Kakamega County Referral Hospitals where a well-
established surveillance system was in place, and
comprehensive data for the full study period was avail-
able (Additional file 2, section 1). We excluded data
from circulation of influenza A(H1N1)pdm09 during the
pandemic period (January 2010 to December 2011) to
focus on seasonal epidemics, because the influenza
A(H1N1)pdm09 pandemic did not present normal influ-
enza activity in Kenya and was associated with higher
level of severity than other circulating strains [18].
Hospitalised patients with SARI were included in the
surveillance system if illness onset was acute (within 14
days from admission date) and they presented with fever
(or history of fever) and cough. Nasopharyngeal (NP)
and oropharyngeal (OP) samples were tested by real-
time reverse transcription-polymerase chain reaction
(rRT-PCR) from a random subset of these hospitalised
patients [9]. Of the 24,480 cases identified through the
SARI surveillance system, 80% were tested for influenza
virus.
We defined hospital-specific catchment populations
around each SARI surveillance site as the population
within 10 kilometres (km) of the hospital. This was in-
formed by a study in Kenya that showed 90% of children
admitted with symptoms of a febrile illness, reside within
10 km of the health facility (Additional file 2, section 1)
[19].
Defining epidemics
Kenya has year-round influenza transmission. To allow
fitting and simulation of vaccine impact in the model,
we used the following activity-period decision rule. We
identified periods of high influenza activity as ≥2 succes-
sive weeks where the proportion of subtype-specific test-
positive cases was greater than the average weekly
proportion during the entire study [20]. A period ended
when there were ≥ 2 consecutive weeks where the pro-
portion of subtype-specific positive cases was less than
the weekly average. In addition, influenza-positive cases
had to be observed in at least 3 of the 5 surveillance sites
during the identified period so that periods identified
were of widespread transmission. During model fitting,
start and end dates were adjusted to centre the model
peak to observed cases. If the posterior mean estimate of
the net reproduction number at the start of the simula-
tion was less than 1 (i.e. little evidence of sustained
transmission), the period was excluded.
Transmission model
We modified an age-stratified Susceptible-Exposed-
Infectious-Recovered (SEIR) compartmental modelling
framework previously used to inform influenza vaccin-
ation policy decision-making in the UK (Additional file
2, section 2) [16, 21]. The main differences between the
UK model and Kenya model and their impact on the
findings are summarised in the supplementary text
(Additional file 2, section 7).
Mixing between age groups was governed by social
contact survey data from Kenya collected from the
coastal region [22]. The latent period was fixed at 0.8
days, and the infectious period at 1.8 days [16]. Probabil-
ity of transmission and the fraction of the population
susceptible varied each season, and the values were esti-
mated during fitting. The SEIR compartments were
stratified into vaccine-naïve and vaccinated populations.
The model is available in the fluEvidenceSynthesis pack-
age in R [23, 24].
Parameter inference
Parameters of the model were fitted to Kenyan surveil-
lance data using Bayesian evidence synthesis [16]. For
each season, we inferred the transmissibility of the virus,
the susceptibility of 3 age groups (≤14 years, 15–49 years,
≥50 years), the initial number of infections, the number
of infections introduced from outside Kenya, the prob-
ability of identifying an influenza-positive patient within
the catchment population in each of 3 age groups (<1
years, 1–5 years, ≥6 years) and the number of subtype-
specific influenza cases in the whole Kenyan population
during each epidemic. We determined the age groupings
for susceptibility and ascertainment based on compari-
sons of the best fit of the model to the observed data.
Where there was more than one circulating subtype
during a season, we fitted the model separately to each
subtype. We ran 500,000 Markov chain Monte Carlo
(MCMC) iterations after a burn in of 200,000. We
thinned the chain to 2% and all results are presented
from 10,000 samples from the joint posterior distribu-
tion. Posterior mean values and 95% Bayesian credible
intervals (CI) are given.
Vaccination component
We considered 12 vaccination strategies using: (i) 3 age
groups: 6–23months, 2–5 years, 6–14 years; (ii) 4 vac-
cination timings: vaccination campaigns in April–June,
October–December, or both (to coincide with NH or
SH vaccine availability), and year-round vaccination
(Table 1). Vaccination coverage levels varied by strategy.
We assumed that year-round vaccination would achieve
higher coverage levels than shorter campaigns due to
longer availability of vaccine and that vaccination cover-
age of older children would be slightly higher than
younger children, based on findings from a demonstra-
tion vaccination programme in Kenya [25]. For biannual
vaccination, we assumed that individuals would only be
vaccinated once per year and that in each vaccination
period only individuals who had not been vaccinated in
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the preceding 12months would receive vaccine. Vaccin-
ation was assumed to occur at a constant rate during the
vaccination period.
We assumed that the NH and SH vaccines provided
“all-or-nothing protection”, i.e. for 80% vaccine effective-
ness (VE), 80% of vaccinated people receive 100% pro-
tection from infection [26]. Protection lasted from the
time of vaccination up to the end of the subtype specific
influenza activity period. Vaccine protection was re-
stricted to an epidemic and was not carried forward to
future epidemics. We assumed that the NH vaccine pro-
vided protection against influenza activity that began be-
tween September of the same year and February of the
next year and did not protect against influenza activity
beginning between March and August. Similarly, the SH
vaccine provided protection against influenza activity
that began between March to August of the same year
and did not provide protection against activity starting
either earlier or later than these months.
Influenza vaccine effectiveness varies each year and
differs across age groups. To simplify the model, we used
subtype-specific published values of overall influenza VE
to set a fixed value of VE in the model as either good
(70%) or poor (42%) in all target age groups. If published
VE was ≥50%, VE was modelled at 70% across all age
groups; however, if VE was < 50%, VE was set at 42% in
the model (Additional file 2, section 3). The choice of a
fixed influenza VE value was informed by a systematic
review and was validated in the original UK study [16].
Economic evaluation
We used an economic evaluation decision tree to cat-
egorise infected individuals as asymptomatic, symptom-
atic with mild illness (upper respiratory tract (URT)
infections) or symptomatic with severe illness (lower re-
spiratory tract (LRT) infections) based on influenza chal-
lenge studies [27]. Those with mild illness were either
seen at an outpatient clinic or were not medically
attended, while patients with severe illness were either
hospitalised or not. All those with mild illness were as-
sumed to recover, while those with severe illness either
recovered or died (Additional file 2, section 4).
We calculated DALYs from disability weights of mild
upper respiratory infection, moderate lower respiratory
tract infection, severe lower respiratory tract infection
and death [28] (Additional file 2, section 4). We esti-
mated the proportion of cases that attended outpatient
clinics or were hospitalised using representative South
African influenza-specific healthcare utilisation data [29]
(Table 2). To estimate costs from a societal perspective,
we used an influenza costing study that described direct
medical costs, healthcare-related costs, and indirect costs
of influenza illness among patients with influenza at-
tending health facilities in Kenya [30] (Fig. 1) (Table 3).
Vaccine administrative costs were obtained from a
vaccine delivery costing study in Kenya and Tanzania
(Table 3) [31]. We set vaccine purchase price at $3 US
dollars (USD) per dose for a multi-dose vial, which was
considered a reasonable price based on available market
prices for the trivalent inactivated vaccine, if obtained
through a negotiated agreement for low- and middle-
income countries (LMICs). We tested the sensitivity of
our results to this cost. Vaccine wastage was assumed to
be 15% [32]. Costs from before 2018 were adjusted to
2018 USD values using the annual Kenya gross domestic
product (GDP) deflator values.
We calculated annual ICERs per DALY averted for all
12 strategies compared to no vaccination (base scenario),
as influenza vaccination was negligible in Kenya during
the study period. We time discounted DALYs by 3%
[33]. Average annual ICERs per DALY averted were cal-
culated for each vaccine strategy. A cost saving output
resulted in an increase in benefit and overall decrease in
total costs incurred. For each strategy, we calculated the
probability that it had the highest INMB at willingness-
to-pay (WTP) thresholds of 1–51% of the 2018 Kenya
GDP per capita (i.e. between $17 and $872 per DALY
averted), and used the results to construct cost-
effectiveness acceptability curves [34]. We then
constructed cost-effectiveness acceptability frontiers
depicting the highest probability for the most optimal
strategy (i.e. the strategy with highest average INMB) [35].
In sensitivity analysis, we calculated DALYs with and
without social weighting and time discounting [33]. So-
cial weighting placed greater value on life lost from 9 to
Table 1 Vaccination scenarios modelled in three age groups and four vaccination timings













Age group I: 6–23 months 30% 30% 45% 60%
II: 2–5 years 35% 35% 50% 65%
III: 6–14 years 40% 40% 55% 70%
Coverage values were set based on influenza vaccination studies in Kenya [25] and local consultation.
NH Northern Hemisphere, SH Southern Hemisphere
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Table 2 Values for disease states and heath utilisation rates used in economic model. Mean and 95% confidence interval (CI) or
proportions are given
Item Measure Value Distribution Reference
Disease states
Proportion of influenza cases that develop any
clinical symptoms
Mean (95% CI) 0.669 (0.583–0.745) Normal [27]
Proportion of influenza cases that develop
upper respiratory tract symptoms/mild illness
Mean (95% CI) 0.588 (0.455–0.708) Normal [27]
Proportion of influenza cases that develop lower
respiratory tract symptoms/severe illness
Mean (95% CI) 0.210 (0.140–0.303) Normal [27]
Proportion of influenza cases with severe illness
that die while hospitalised
< 1 year Mean (95% CI) 0.0274 (0–0.0616) Truncated normal Influenza SARI surveillance
dataset (2010–2018)
1–5 years Mean (95% CI) 0.0091 (0–0.0322)
6–14 years Mean (95% CI) 0.0108 (0–0.0902)
15–20 years Mean (95% CI) 0 (0–0.1116)
20–49 years Mean (95% CI) 0.0331 (0–0.0818)
≥ 50 years Mean (95% CI) 0.1818 (0.0909–0.3080)
All ages Mean (95% CI) 0.0200 (0.0035–0.0373)
Proportion of deaths due to a respiratory illness
that occur in a health facility
< 1 year Mean (95% CI) 0.2794 (0.2451–0.3140) Normal Siaya health demographic
and surveillance site dataset
(2010–2016)1–5 years Mean (95% CI) 0.2899 (0.2471–0.3349)
6–14 years Mean (95% CI) 0.4361 (0.3534–0.5278)
15–20 years Mean (95% CI) 0.5250 (0.3750–0.6795)
20–49 years Mean (95% CI) 0.5067 (0.4626–0.5525)
≥ 50 years Mean (95% CI) 0.2715 (0.2421–0.3012)
All ages Mean (95% CI) 0.3287 (0.3106–0.3474)
Health care utilisation events
Proportion of symptomatic influenza cases who
attend outpatient clinic
0–5 years Mean (95% CI) 0.475 (0.39–0.60) Normal [29]
6–12 years Mean (95% CI) 0.118 (0.09–0.17)
13–17 years Mean (95% CI) 0.088 (0.06–0.13)
18–24 years Mean (95% CI) 0.035 (0.02–0.08)
25–44 years Mean (95% CI) 0.034 (0.02–0.07)
45–64 years Mean (95% CI) 0.027 (0.01–0.05)
≥ 65 years Mean (95% CI) 0.036 (0.02–0.07)
Proportion of symptomatic influenza cases
who are hospitalised
0–5 years Mean (95% CI) 0.0102 (0.0089–0.0117) Normal [29]
6–12 years Mean (95% CI) 0.0007 (0.0006–0.0010)
13–17 years Mean (95% CI) 0.0006 (0.0004–0.0011)
18–24 years Mean (95% CI) 0.0008 (0.0006–0.0010)
25–44 years Mean (95% CI) 0.0021 (0.0018–0.0024)
45–64 years Mean (95% CI) 0.0026 (0.0020–0.0033)
≥ 65 years Mean (95% CI) 0.0033 (0.0025–0.0044)
Proportion of outpatient influenza cases who
purchased medication prior to clinic visit
Proportion 0.718 Fixed value [30]
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56 years of age. We tested the impact of changing the vac-
cine purchase price to $1.5, $3.0, $6.0 and $10.0 per dose.
Finally, we tested the impact of maintaining the same vac-
cine coverage across all age groups, i.e. 30% coverage for
once yearly campaigns, 45% coverage for twice yearly
campaigns and 60% for year-round vaccination.
Ethics statement
Permission to undertake secondary data analysis of de-
identified SARI surveillance data collected from patients
admitted at county referral hospitals, was obtained from
the Kenyatta National Hospital – University of Nairobi
Ethics Review Committee (P18/01/2017).
Results
Periods of high influenza activity
We fitted 11 periods of high influenza activity in 7
of the 9 years of surveillance data. Five periods were
associated with influenza B, four with A(H3N2) and
two with A(H1N1)pdm09 (Fig. 2). In 1 year, there
were 3 peaks in activity (September 2017–August
2018), and in 2 years, there were two peaks in
Table 2 Values for disease states and heath utilisation rates used in economic model. Mean and 95% confidence interval (CI) or
proportions are given (Continued)
Item Measure Value Distribution Reference
Proportion of hospitalised influenza cases who
sought care after discharge from hospital
Proportion 0.105 Fixed value [30]
Proportion of non-medically attended influenza
cases where household members missed work
due to illness*
Proportion Not known – –
Proportion of outpatient influenza cases where
household members missed work due to illness
Proportion 0.518 Fixed value [30]
Proportion of hospitalised influenza cases where
household members missed work due to illness
Proportion 0.848 Fixed value [30]
Proportion of non-medically attended influenza
cases where household members paid for
childcare during illness*
Proportion Not known – –
Proportion of outpatient influenza cases where
household members paid for childcare during illness
Proportion 0.18 Fixed value [30]
Proportion of hospitalised influenza cases where
household members paid for childcare during illness
Proportion 0.29 Fixed value [30]
*These items were not included in the model as the values were unknown and difficult to estimate in the case of non-medically attended illness
Fig. 1 Summary of costs associated with influenza illness and vaccination. Shading of boxes: white = direct medical costs paid by government
(presupposes a universal healthcare scheme with government as the main healthcare payer), blue = healthcare-related costs paid by individual,
orange = indirect costs paid by individual
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activity (September 2010–August 2011, and Septem-
ber 2015–August 2016). September 2014–August
2015 and September 2016–August 2017 had no
influenza activity periods that met the activity-period
decision rule. The remaining 3 years had one period
of influenza activity each (Table 4, Additional file 2
section 5).
Of the 11 periods of high influenza activity, 6 started
between September and February and were suited to
vaccination with the NH vaccine, and 5 started between
March and August and were suited to the SH vaccine
(Table 4). There were 8 instances where limited influ-
enza activity did not meet the activity decision criteria
(Additional file 2, section 5).
Disease burden in the absence of vaccination
We estimated that the mean number of infections per
year (includes asymptomatic and symptomatic infec-
tions) was 2.0–15.0 million (Fig. 3, and Additional file 3,
table 1), corresponding to a mean annual attack rate of
5–32%. For years where more than one period of high
influenza activity was modelled, the mean annual num-
ber of infections was 5.7–15.0 million and the mean an-
nual attack rate was 12–32%, while for years that had
one peak, the yearly average was 2.0–6.7 million infec-
tions with a mean annual attack rate of 5–16%.
We estimated that the average annual rate of infection
was 4547–32,343 per 100,000 population. Rates of infec-
tion were highest among children 1–5 years (Additional
Table 3 Cost of influenza-associated illness in US dollars showing year of valuation
Type of cost Measure Value in USD Year Distribution Source
Direct medical costs
Facility based medical costs among influenza cases
attending outpatient clinic
Mean (SD) 4.34 (1.30) 2014 Normal [30]
Facility based medical costs among hospitalised influenza cases Mean (SD) 59.19 (59.39) 2014 Normal [30]
Health care costs after discharge among hospitalised influenza
cases who sought care after discharge
Mean (SD) 3.28 (6.19) Normal [30]
Influenza vaccine purchase costs per dose
(varied in sensitivity analysis)
Fixed 3 2018 Fixed value Assumption
Vaccine administration cost per dose
Supply chain cost per dose from national level to the
health facility
Mean 0.43 2012 Fixed value [31]
Provision of immunisation services at the health facility Mean (SD) 1.0 (0.72) 2012 Normal [31]
Health care related costs
Transportation costs among influenza cases attending
outpatient clinic
Mean (SD) 0.40 (0.87) 2014 Normal [30]
Transportation costs among hospitalised influenza cases Mean (SD) 5.03 (8.32) 2014 Normal [30]
Transportation costs to receive vaccine at health facility Man (SD) 0.20 (0.435) 2014 Normal Assumption*
Health care costs prior to outpatient visit among influenza
cases who purchased medication before the outpatient visit
Mean (SD) 1.39 (3.90) 2014 Normal [30]
Indirect costs
Lost wages among influenza cases not seeking formal health
care for mild illness
Fixed 0 – Fixed value Assumption
Lost wages among influenza cases attending outpatient visit
who report that household members missed work
Mean (SD) 12.84 (27.17) 2014 Normal [30]
Lost wages among hospitalised influenza cases who report
that household members missed work
Mean (SD) 42.02 (41.54) 2014 Normal [30]
Lost wages among those not hospitalised with severe
influenza illness
– Not known – – –
Childcare costs among influenza cases attending outpatient
clinic who report household members paid for childcare
Mean (SD) 0.07 (0.57) 2014 Normal [30]
Childcare costs among hospitalised influenza cases who report
household members paid for childcare
Mean (SD) 0.11 (0.75) 2014 Normal [30]
Childcare among those not hospitalised for severe influenza illness – Not known – – –
*For this cost no data existed and an assumption was made that the cost would be half of the transportation costs for outpatient care
In the case where no data was available for costs incurred by non-medically attended cases, these costs were not included in the model
SD standard deviation
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Fig. 2 Comparison of the fit of the model to weekly influenza-positive SARI cases in all ages. Positive cases detected in the influenza surveillance
system (black) with hypergeometric 95% confidence interval. Lines and shading represent the median (red) and 50% (green) and 75% credible
intervals (blue) of the fitted model. Note that the model is fitted to age-specific data, but age groups are aggregated here for clarity. a Influenza
B. b Influenza A(H3N2). c Influenza A(H1N1)pdm09). Influenza A(H1N1)pdm09) data from January 2010 to December 2012 were excluded from
the analysis
Table 4 Periods of high influenza activity, 2010–2018
Year NH season Subtype Vaccine match SH season Subtype Vaccine match
Jan 2010–Aug 2010 03/2010–12/2010 A(H3N2) M
2010–2011 12/2010–08/2011 B M 08/2011–03/2012 B M
2011–2012 12/2011–05/2012 A(H3N2) U
2012–2013 05/2013–12/2013 B M
2013–2014 12/2013–09/2014 A(H1N1)pdm09 M
2014–2015
2015–2016 11/2015–05/2016 B M 03/2016–11/2016 A(H3N2) U
2016–2017
2017–2018 09/2017–06/2018 B U 06/2018–12/2018 A(H3N2)* U
01/2018–10/2018 A(H1N1)pdm09 M
An influenza year begins in September and ends in August the following year. “M” means the vaccine was well matched to circulating strains (VE = 70%) [16]. “U”
means vaccine was poorly matched to circulating strains (VE = 42%) [16]. Blank cells indicate no detectable peak in influenza activity. *There were no SH VE
estimates available at the time, and we used VE values for the NH vaccine
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file 3, table 2). There were 1.1–8.5 million upper respira-
tory tract infections, 0.5–3.7 million lower respiratory
tract infections and 570–3626 deaths annually (Fig. 3).
Deaths were highest in the 1–5 and >50 age groups. The
average annual mortality rate was 1–8 per 100,000 popu-
lation. The highest mortality rates were observed in the
≥50, <1 and 1–5 age groups (Additional file 3, table 2).
There were 24,000–163,000 DALYs associated with
influenza illness each year. Children 1–5 years of age
consistently contributed the highest number of DALYs
(Additional file 3, table 1).
There were 0.3–1.6 million outpatient visits and
5000–32,000 hospitalisations across all age groups each
year (Fig. 3). The highest number of hospitalisations was
observed among children 1–5 years of age (Additional
file 3, table 3). The annual mean rate of hospitalisation
Fig. 3 Influenza burden in the absence of vaccination in all age groups, 2010–2018. Mean and 95% credible interval shown for each calendar
year (September–August). a Influenza infections, upper respiratory tract infections and lower respiratory tract infections. b Deaths. c DALYs. d
Outpatient visits. e Hospitalisations. f Costs. Note that y-axes vary. There were three periods of high influenza activity in Sep 2017–Aug 2018, two
periods of high influenza activity in Sep 2010–Aug 2011 and Sep 2015–Aug 2016. Years with no detectable periods of high influenza activity are
not included in the figure
Dawa et al. BMC Medicine          (2020) 18:223 Page 9 of 19
across all ages was 12–70 per 100,000 population and
was highest among children 1–5 years of age followed
by those < 1 year of age (Additional file 3, table 2).
Costs of influenza illness
We estimated that the direct medical costs associated
with outpatient and inpatient care were $2.0–$11.6
million per year (Fig. 3 and Additional file 3, table 4). Of
this amount, outpatient costs accounted for approxi-
mately three quarters of total direct medical costs.
Healthcare-related costs amounted to $0.6–$3.2 million
annually while indirect costs associated with lost wages
and childcare costs equalled $5.1–$29.6 million per year.
The mean annual total cost of influenza-associated ill-
ness was $20.3 million each year (annual average ranged
between $7.6 and $44.5 million). Of note, indirect costs
accounted for nearly 60% of all influenza-associated
costs (Fig. 3 and Additional file 3, table 4).
Comparison of vaccination strategies
There were substantial differences in mean costs and
outcomes by strategy (Fig. 4). Mean annual vaccination
purchase and administrative costs were lower when vac-
cinating children 6–23 months (strategy I: $4.3–$10.5
million) compared to 2–5-year-olds (strategy II:
$9.9–$22.7 million) and 6–14-year-olds (strategy III:
$25.3–$54.4 million) (Additional file 3, table 5). Total
societal costs associated with vaccination and illness
were lowest with strategy I as compared to the other
strategies: it cost an annual average of $10.5–$53.4
million for strategy I, $14.5–$63.2 million for strategy II
and $28.7–$87.8 for strategy III (Table 5). Strategy III
(vaccinating 6–14 year olds) required the highest
Fig. 4 Summary of annual mean incremental cost, reductions in infections and vaccine doses per strategy. a Annual reduction in number of
infections and incremental total societal costs per strategy. b Annual reduction in number of infections and vaccine doses per vaccine strategy. c
Annual incremental total societal costs and vaccine doses costs per strategy. Strategies are vaccinating children 6–23 months (strategy I), 2–5
years (strategy II) and 6–14 years (strategy III) with either the Southern Hemisphere influenza vaccine (Strategy A) or Northern Hemisphere vaccine
(Strategy B) or both (Strategy C: twice yearly 3-month vaccination periods, or Strategy D: year-round vaccination). The points mark posterior mean
estimates and lines 95% credible intervals






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Dawa et al. BMC Medicine          (2020) 18:223 Page 11 of 19
number of vaccine doses, resulted in the highest costs
and led to the largest decrease in the number of infec-
tions (Fig. 4).
When vaccination was well timed/aligned to influenza
activity, the annual mean ICER per DALY averted
ranged between $749 and $1385 per DALY averted for
strategy IA, $442 and $1877 for strategy IB, $678 and
$4106 for strategy IC and $1147 and $7933 for strategy
ID. For II strategies, it ranged between $945 and $1573
for strategy IIA, $563 and $1869 for strategy IIB, $662
and $4085 for strategy IIC and $1169 and $7897 for
strategy IID. For III strategies, it ranged between $923
and $3116 for strategy IIIA, $1005 and $2223 for strat-
egy IIIB, $883 and $4727 for strategy IIIC and $1467
and $6813 for strategy IIID (Additional file 3, table 6).
There was considerable overlap between ICER values
obtained for each strategy in the 7 years with influenza
activity (Fig. 5 and Additional file 3, table 6). Depending
on the strategy, 0–3% of outputs were cost saving, and
only 15–39% of outputs were equal to or less than the
upper limit of the WTP threshold of $872 (51% of an-
nual GDP per capita). Using the average INMB values,
vaccination was not cost-effective in 2011–2012 at the
tested WTP thresholds (Additional file 2, section 6).
When comparing age groups, I strategies (vaccinating
children 6–23 months of age) had the highest mean
INMB values at the lowest WTP values in 5 of 7 years;
however in 2015–2016, III strategies (vaccinating 6–14
year olds) had the highest mean INMB at the lowest
WTP value (Additional file 2, section 6 and
Fig. 5 ICER per DALY averted and 95% CI. Results for 2014–15 and 2016–17 are not shown as there were no periods of high influenza activity
detected in these years and calculation of ICER values per DALY averted would produce an infinite value as no DALYs would be averted. Similarly,
ICER values are not shown for A and B strategies where vaccine administration was mistimed to influenza activity as vaccination was considered
ineffective that year. Note the y-axes are cut off at 10,000 while actual values may exceed this value. Section shaded grey between the horizontal
dotted lines represents outputs that fall within a willingness-to-pay threshold of 1–51% of the GDP per capita (i.e. between $17 and $872). Values
below zero are cost saving. Strategies are vaccinating children 6–23 months (strategy I), 2–5 years (strategy II) and 6–14 years (strategy III) with
either the Southern Hemisphere influenza vaccine (Strategy A) or Northern Hemisphere vaccine (Strategy B) or both (Strategy C: twice yearly 3-
month vaccination periods, or Strategy D: year-round vaccination)
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Additional file 4). In regard to timing of vaccination, A
strategies (April–June) and B strategies (October–De-
cember) had the highest mean INMB at the lowest WTP
values in an equal number of years. C strategies (vaccin-
ating in two 3-month campaigns) were the most cost-
effective strategies at the upper WTP limit ($872) in
2010–2011, 2015–2016 and 2017–2018; however, D
strategies were never cost-effective at Kenya’s range of
WTP values (Additional file 2, section 6). On average,
across the 7 years of influenza activity, no vaccination
strategy was cost-effective at $17 (lower limit of WTP
range), and $445 (median value of WTP range). At $872
(upper limit of WTP range), strategy IB had the highest
mean INMB; however, it had low probability (3%) of be-
ing the most optimal strategy (Fig. 6, Table 6).
The most favourable vaccination strategy each year
was the same regardless of whether total societal costs
or only direct medical costs were considered
(Additional file 5); however, the WTP value at which
vaccination became cost-effective was higher with direct
medical costs (Additional file 2, section 6). Based on the
average INMB values across the 7 years of influenza ac-
tivity, no vaccination strategy was cost-effective at the
upper limit of the WTP threshold when only direct
medical costs were considered.
Sensitivity analysis
Removing time discounting led to a 49–50% reduction
in mean ICER per DALY averted across all strategies,
and addition of social weighting led to a slight decrease
(5–6%) in mean ICER value. At a vaccine purchase price
of $1.50 USD, the mean ICER decreased by 44–62%. At
a vaccine purchase price of $10.0 USD, the mean ICER
value increased by 144–178%, and at $6.0 USD, the
mean ICER value increased by 38–43%, while at a vac-
cine purchase price of $4.50 USD the mean ICER value
Fig. 6 Cost-effectiveness acceptability curve and frontier for strategies with the highest incremental net monetary benefit. a Cost-effectiveness
acceptability curve. b Cost-effectiveness acceptability frontier. NB: X axis is limited to 1000 USD per DALY averted. Strategies are vaccinating
children 6–23 months (strategy I), 2–5 years (strategy II) and 6–14 years (strategy III) with either the SH influenza vaccine (Strategy A) or NH
vaccine (Strategy B) or both (Strategy C: twice yearly 3-month vaccination periods, or Strategy D: year-round vaccination)
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increased by 31–38%. Maintaining a uniform vaccine
coverage across all age groups led to a 1–4% decrease in
mean ICER value for strategies targeting children 2–5
years, and a 7–20% reduction in mean ICER values for
strategies targeting children 6–14 years. Using the INMB
approach, no vaccination strategy was cost-effective at a
vaccine price of $4.5 USD and above. For all other sensi-
tivity analysis outputs, vaccinating children 6–23months
of age with the NH vaccine (strategy IB) remained the
most cost-effective strategy.
Discussion
There were yearly variations in peaks of influenza activ-
ity, with at most three periods of increased influenza ac-
tivity each year. Rates of infection and hospitalisation
were highest in the 1–5 year age group, while mortality
rates were highest in individuals ≥50 and children <5. As
a result, children 1–5 years contributed the highest num-
ber of DALYs each year. Given the expected vaccine
coverage levels, we found that targeting children 6–23
months in an annual 3-month campaign was the most
favourable of the vaccination strategies, although the
probability of any vaccination strategy being cost-
effective, even at the upper limit of the WTP threshold,
was low. Vaccination was most cost-effective when vac-
cine was well matched to circulating strains and influ-
enza activity occurred after hypothetical vaccination
campaigns. Vaccinating children 6–23 months of age
was least expensive although the reduction in number of
infections was not as substantial as those observed at
higher coverage levels attainable by vaccinating more
children in older age groups. The provisional KENITAG
recommendation to vaccinate children 6–23months
would be the least expensive strategy for the government
to adopt and frequently had the highest INMB, although
at very low probabilities.
Primary school-going children have the highest con-
tact rates in Kenya [22], and therefore, vaccinating this
group could yield considerable benefit in all ages due to
indirect protection [36]. We found that the overall reduc-
tion when vaccinating children 6–14 years old was only
more favourable than vaccinating children 6–23months
of age (who have a higher burden of severe disease) in
2015–2016 when the vaccine was poorly matched to cir-
culating strains. Vaccinating school-going children may be
an important strategy when inadequate protection levels
are attained in those most susceptible to severe disease
[37]. Nonetheless, we found that when the vaccine is well
matched to circulating strains, direct protection of the age
group with highest burden of severe disease was most
favourable. Studies have previously shown that with lower
vaccine efficacy the indirect benefit of vaccination exceeds
the direct benefits by larger margins [13] and could ex-
plain why we obtained more favourable values when vac-
cinating children 6–14 years of age in years when vaccine
effectiveness was lower.
We found that year-round vaccination was always the
least cost-effective strategy. For this strategy, vaccination
after infection was more likely to occur. Therefore, vac-
cinating in short 3-month campaigns was a more
Table 6 Incremental net monetary benefit values and probabilities for each vaccination strategy at a willingness-to-pay threshold of










Lower quantile Upper quantile
Strategy IA − 472 − 6201 10,054 4% 5
Strategy IB 3 − 5975 13,302 3% 1
Strategy IC − 217 − 6976 13,545 0% 3
Strategy ID − 3424 −10,351 9188 0% 8
Strategy IIA − 1293 −14,377 23,996 11% 7
Strategy IIB − 581 −13,854 28,726 7% 6
Strategy IIC − 387 −15,597 31,947 2% 4
Strategy IID − 7507 −22,440 20,834 0% 11
Strategy IIIA − 7077 −36,674 53,262 12% 10
Strategy IIIB − 7531 −35,320 44,647 12% 12
Strategy IIIC − 3633 −39,244 70,255 14% 9
Strategy IIID − 20,326 −54,467 42,876 0% 13
No vaccine 0 – – 35% 2
INMB incremental net monetary benefit. Strategies are vaccinating children 6–23 months (strategy I), 2–5 years (strategy II) and 6–14 years (strategy III) with either
the Southern Hemisphere influenza vaccine (Strategy A) or Northern Hemisphere vaccine (Strategy B) or both (Strategy C: twice yearly 3-month vaccination
periods, or Strategy D: year-round vaccination)
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favourable strategy than year-round vaccination. These
findings highlight the need to vaccinate as much of the
target population as possible as soon as the influenza
vaccine becomes available in order to enjoy the full
benefit of vaccination in Kenya. However, evidence of
intraseasonal waning immunity and its implications on
vaccination timing may lead to changes in recommenda-
tions for vaccination timings in future [38–40].
Vaccinating twice a year was most cost-effective at
higher WTP values. This strategy would ensure that a
proportion of the population has some protection
against the currently circulating influenza strains by
using the most up-to-date vaccine formulation. Continu-
ous mutations in nucleic acids coding for influenza
antigens lead to semi-annual reviews of the components
used for the production of influenza vaccine [41]. Over
the past 10 years, the strains in the NH vaccine differed
from the incoming SH vaccine in 6 years and differed
from the contents of the preceding SH vaccine in 3 years
[42]. Despite the possibility of waning protection [43–
45], vaccinating once per year should provide some pro-
tection over a 12-month period if there is no need for a
change in the composition of the NH and SH vac-
cine. Once-a-year vaccination in short 3-month cam-
paigns should be considered; however, surveillance is
needed to monitor whether the vaccine is well
matched to circulating strains that circulate in the lat-
ter half of the year.
In this study, most of the model outputs were unlikely
to be cost-effective given a willingness-to-pay threshold
of 1–51% of the GDP. These findings were contingent
on a vaccine price per dose of $3, which is lower in price
than vaccine available in high-income countries [46].
Very few outputs (1% of all simulations) at the price of
$3 were cost saving. Overall, vaccination was unlikely to
be cost-effective; however, if we had used previous
WHO thresholds for cost-effectiveness of health inter-
ventions (i.e. (i) very cost-effective if less than the annual
GDP per capita, (ii) cost-effective if 1–3 times the GDP,
and (iii) not cost-effective if greater than 3 times the
GDP [47]), we would have found that vaccination was
most likely very cost-effective or cost-effective regardless
of the strategy modelled. However, there is debate over
the suitability and affordability of the WHO threshold
for cost-effectiveness of interventions in LMICs [47, 48]
and as an alternative a threshold of 1–51% GDP per
capita for LMICs has been proposed [34]. This lower
threshold is postulated to better reflect the con-
straints within the “supply side” of healthcare funding
and considers the opportunity costs of the choice of
interventions [34]. Selecting an appropriate ICER
threshold value is critical: if interventions that cost
more than the appropriate ICER threshold are imple-
mented, they result in a net reduction in health, as
more health benefits could be gained by choosing in-
terventions of a lower ICER value [49].
Influenza vaccination of children 6–23 months age was
cost-effective at a WTP value of $872 per DALY averted,
while vaccines already included in the Kenya expanded
programme on immunisation (EPI) have considerably
lower ICER values. For example, rotavirus vaccine and
Haemophilus influenzae type b vaccine cost approxi-
mately $38 per DALY averted [50, 51], while the
pneumococcal vaccine costs $59 per DALY averted [52].
Continuing the pneumococcal vaccination programme
beyond 2022–2027 when Kenya transitions to the full
Gavi price ($3.05 per dose) would still result in a cost
per DALY averted of $153 (95% prediction intervals of
$70–$411) [53].
In 2010, half of the vaccines provided or considered
for provision in LMICs cost less than $100 per DALY
averted, 25% cost between $100 and $500 per DALY
averted and 9% cost between $500 and $1000 per DALY
averted (2010 dollar values) [54]. A decrease in vaccine
price and improved influenza vaccine effectiveness, dur-
ation of protection, and if possible, long-term immunity
would increase influenza vaccine cost-effectiveness and
likely adoption in LMICs [55].
Although the range of ICER values per DALY averted
were similar among the strategies, the modelled vaccin-
ation strategies substantially differed in vaccine purchase
costs. Over the past 3 years (2016–2019), the govern-
ment of Kenya allocated approximately $7 million per fi-
nancial year to the immunisation programme, while
Gavi contributed $26 million per year [56]. We esti-
mated that at a vaccine price of $3 per dose, the govern-
ment would spend $4.3–$10.5 million in vaccine
purchase costs for the least expensive strategy, and
$25.3–$54.4 million for the most expensive strategy,
which represents a significant proportion of the immun-
isation budget. Cost differences between strategies could
therefore influence selection of vaccination strategy.
Our findings need to be interpreted in light of several
limitations. In 2014–2015 and 2016–2017, influenza ac-
tivity did not meet our decision rule for periods of activ-
ity. These periods were characterised by nationwide
healthcare worker strikes in public hospitals and disrup-
tions in influenza surveillance funding (2014–2015),
both of which plausibly led to a decrease in the number
of influenza-positive SARI patients detected. Therefore,
our model could have underestimated the burden of in-
fluenza and the impact and cost-effectiveness of seasonal
influenza vaccination. Indeed, we were not able to fit all
the observed periods of influenza activity, which could
also underestimate the impact of vaccination over those
periods. More complete and robust surveillance data
could improve estimates and give further confidence in
the findings presented here.
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We limited our burden calculation to periods of high
influenza activity. However, the overall rates of hospital-
isation across all ages are comparable to past estimates
of national disease burden conducted in Kenya covering
similar years [1, 57]. Using a simpler methodology that
took into account influenza activity throughout the year,
we previously estimated the mean annual rates of
influenza-associated hospitalised SARI to be 21 (95%
confidence limit 19–23) per 100,000 population over the
period January 2012–December 2014 [1]. For a similar
period in our study, September 2011–August 2014, we
estimated the mean annual influenza hospitalisation
rates to be 24 per 100,000. These similar results may be
explained by the fact that the identified periods of high
influenza activity frequently lasted 6 or more months,
and likely captured most of the annual influenza activity.
Although we focussed on peaks in activity, we obtained
comparable rates of illness to studies that considered
year-round activity. However, our rates of hospitalised
influenza during the early years of this study were
slightly lower than previous estimates from August 2010
to July 2011, when published rates of influenza-
associated hospitalised SARI were 70 (95% confidence
limits 50–90) per 100,000 persons [57]. Our estimated
rate for the period September 2010–August 2011 was 39
(95% credible interval 17–69) per 100,000 persons. This
disparity may be explained by the fact that we excluded
circulation of A(H1N1)pdm09 from January 2010 to
December 2011 during our analysis. We excluded the
first 2 years of circulation of the pandemic strain be-
cause these epidemics were not a typical influenza sea-
son—there was no single peak and numerous small
epidemics occurred. This exclusion could have led to
underestimation of vaccine cost-effectiveness if vaccines
were matched to the pandemic strain during this time.
Additionally, if competitive viral interaction were occur-
ring, the circulation of A(H1N1)pdm09 could have sup-
pressed A(H3N2) or B epidemics, leading to
underestimation of vaccine impact.
In this analysis, we assumed that vaccination with SH
or NH vaccine did not protect against transmission
starting in the alternate hemisphere’s vaccination period.
This assumption was informed by the potential for wan-
ing immunity suggested by declining vaccine antibody ti-
tres [58, 59] and/or possible mismatch of vaccine
composition to circulating subtypes [42]. If there were
lasting protection [60], there would be a higher impact
of the vaccine in later seasons and an increase in cost-
effectiveness. On the other hand, for periods of influenza
activity that fell within a particular vaccination period,
we also assumed protection was maintained at a con-
stant level for the duration of influenza activity, regard-
less of whether the epidemic ran into the next
vaccination period, i.e. even when periods of influenza
activity lasted more than 6months. This could lead to
overestimation of the impact of vaccination.
We adopted a societal perspective for costs. However,
we did not have local data on over-the-counter medica-
tion costs, lost wages and childcare costs for non-
medically attended symptomatic influenza cases, and
these costs were not incorporated in the analysis. The
lack of local data may have led to underestimation of
costs as well as the benefits of vaccination. We assumed
vaccine completely protects a proportion of those vacci-
nated, i.e. “all-or-nothing” protection. However, where
the influenza vaccine does not prevent infection, it may
still reduce the severity and duration of illness [61]
which could have underestimated the benefit of vaccin-
ation. Finally, we did not include non-respiratory influ-
enza illness in our analysis. Although they are important
manifestations of severe influenza, they contribute only
7% of the total costs of illness and may not have made
significant differences to the ICER values [62].
Conclusion
Influenza vaccination of children 6–23months of age
once per year was the most favourable vaccination strat-
egy; however, it is unlikely to be a cost-effective inter-
vention using a WTP threshold of 1–51% of annual
GDP per capita. Targeting children in older age groups
led to the largest reduction in the number of cases but
was not necessarily the most cost-effective strategy at
our WTP threshold. Further reductions in cost per dose
and improvements in vaccine effectiveness and long-
term immunity would make the influenza vaccine more
attractive for inclusion in the EPI.
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Additional file 5. Yearly cost-effectiveness acceptability curves and fron-
tiers for strategies with the highest incremental net monetary benefit
considering direct medical costs only. NB: X axis is limited to 1000 USD
per DALY averted. Strategies are vaccinating children 6–23 months (strat-
egy I), 2–5 years (strategy II) and 6–14 years (strategy III) with either the
SH influenza vaccine (Strategy A) or NH vaccine (Strategy B) or both
(Strategy C: twice yearly 3-month vaccination periods, or Strategy D: year-
round vaccination).
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